Ligand Pharmaceuticals Incorporated (LGND) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Current Price
$202.09
Price Target
$248.00
Target Range
$230.00 — $275.00
Analyst Rating
Buy
Forward P/E23.8x
Trailing P/E-918.6x
Forward PEG—
Implied Growth+252.5%
Median Target$239.00
Analyst Spread18.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$230
+13.8%
Consensus
$248
+22.7%
Bull Case
$275
+36.1%
LGND Price Target Analysis
Updated March 4, 2026As of March 4, 2026, Ligand Pharmaceuticals Incorporated (LGND) has a Wall Street consensus price target of $248.00, based on estimates from 16 covering analysts. With the stock currently trading at $202.09, this represents a potential upside of +22.7%. The company has a market capitalization of $3.97B.
Analyst price targets range from a low of $230.00 to a high of $275.00, representing a 18% spread in expectations. The median target of $239.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, LGND trades at a trailing P/E of -918.6x and forward P/E of 23.8x. Analysts expect EPS to grow +252.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+92.5%
Avg Forward P/E24.5x
Peers with Coverage5 / 8
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
| LGNDLigand Pharmaceuticals Incorporated | $4.0B | $202.09 | $248.00 | +22.7% | Buy | 23.8x | 16 |
 RPRXRoyalty Pharma plc | $7.1B | $47.26 | $49.40 | +4.5% | Buy | 9.7x | 11 |
 INVAInnoviva, Inc. | $1.7B | $22.25 | $32.50 | +46.1% | Buy | 11.3x | 10 |
 BTXBlackRock Technology and Private Equity Term Trust | $765M | $6.55 | — | — | — | — | — |
 XOMAPXOMA Corporation | $321M | $26.06 | — | — | Buy | 39.1x | 9 |
 XOMAXOMA Royalty Corp. | $305M | $25.54 | $68.25 | +167.2% | Buy | 38.3x | 10 |
 CBUSCibus, Inc. | $106M | $3.57 | $11.50 | +222.1% | Buy | — | 3 |
 CDTCDT Equity Inc. | $30M | $0.60 | — | — | — | — | — |
Upside Potential Comparison
CBUSXOMAINVALGNDRPRXSee LGND's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LGND Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare LGND vs AGIO
See how LGND stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
What is the LGND stock price target for 2026?
The consensus Wall Street price target for LGND is $248, representing 22.7% upside from the current price of $202.0875. With 16 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is LGND a buy, sell, or hold?
LGND has a consensus rating of "Buy" based on 16 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $248 implies 22.7% upside from current levels.
Is LGND stock overvalued or undervalued?
LGND trades at a forward P/E of 23.7991x, representing a moderate valuation. With analysts targeting $248 (22.7% implied move), the stock appears reasonably valued with upside.
How high can LGND stock go?
The most bullish Wall Street analyst has a price target of $275 for LGND, while the most conservative target is $230. The consensus of $248 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover LGND stock?
LGND is well covered by analysts, with 16 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the LGND stock forecast?
The 12-month LGND stock forecast based on 16 Wall Street analysts shows a consensus price target of $248, with estimates ranging from $230 (bear case) to $275 (bull case). The median consensus rating is "Buy".
What is LGND's forward P/E ratio?
LGND trades at a forward P/E ratio of 23.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy LGND stock?
Wall Street analysts are very optimistic on LGND, with a "Buy" consensus rating and $248 price target (22.7% upside). 11 of 16 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do LGND price targets vary so much?
LGND analyst price targets range from $230 to $275, a 18% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $248 consensus represents the middle ground.